|Age:||18 years or older|
|Keywords:||kidney transplant, renal transplant rejection, kidney rejection, anti-rejection medication|
|Type:||Drug study, Phase 4|
There will be 2 study groups. The chance of being in each study group will be 2:1 and you will be randomly assigned to a treatment based on chance. Neither you nor the study investigators choose your assigned group.
As long as you remain eligible for the study, you will receive your study medication from the study team for the one year study duration:
You will start receiving your study medication before you leave the hospital after your transplant surgery.
Inclusion Criteria 1. Signed informed consent and or/assent 2. Between the ages of 18 and 70 years, inclusive 3. Current or future kidney transplant recipients, no more than 14 days after transplant and prior to hospital discharge. Inclusion of future kidney transplant recipients cannot exceed 30-days pre-transplant. 4. Able to swallow tablets and capsules at the time of randomization 5. Subjects must be receiving a primary or secondary kidney allograft from a deceased donor or from a non- HLA identical living donor 6. Negative cross match test, and compatible (A, B, AB or O) blood type 7. Subjects must have no known contraindications to tacrolimus 8. Women of childbearing potential (WOCBP) must have a negative pregnancy test and be willing to use 2 methods of contraception during the study and for 6 weeks after stopping the study drug.
Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.